MIND Foundation’s INSIGHT Conference took place from August 31 to September 3 in Berlin, exploring the latest frontiers in psychedelic medicines – from clinical developments to...
Kernel has published results from its Cybin-sponsored neuroimaging study which show the ability of Kernel’s Flow1 system to capture and analyse brain changes induced by psychedelics.
At PSYCH Symposium in the British Museum on 6 July, the panel ‘Neuroimaging & Psychedelics: The Past, Present & Future’ explored how neuroimaging can inform our...
Doug Drysdale, CEO of Cybin Inc.,
Cybin has announced key highlights from its study evaluating Kernel’s Flow wearable technology to measure ketamine’s psychedelic effect on cerebral cortex hemodynamics.
How do treatments for mood and anxiety disorders derived from psilocybin exert their effects in the brain?
A researcher at Cornell University is using optical microscopy and other tools to map the brain’s neural response to psychedelics.
The hallucinogenic effect of psychedelics may hold much healing potential, but researchers believe that these compounds could be beneficial for brain disorders without hallucinations.
With growing scientific interest in the area of psychedelics, Duke University has launched the Center for Integrated Psychedelic Science (CIPS).
Biotechnology company Beckley Psytech has welcomed neuroscience expert Dr Frank Wiegand to its team as Chief Medical Officer.